Lipid and hemolysis parameters predicting acute chest syndrome in adulthood with sickle cell disease.
Acute chest syndrome
Hemolysis
Inflammatory
Lipid parameters
Sickle cell disease
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
15
02
2024
accepted:
06
05
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
epublish
Résumé
Sickle cell disease (SCD) is a lifelong blood disorder affecting approximately 100,000 people in the United States and is one of the most common monogenic diseases. A serious complication of SCD is acute chest syndrome (ACS). ACS is a condition with a high rate of morbidity and mortality. The aim of the study was to assess hemolysis and lipid parameters in a cohort of confirmed SCD patients to predict ACS development in the following year.Standard lipid were performed (triglycerides, total cholesterol, high-density cholesterol, low-density cholesterol) panel to calculate of non-HDL-C, large buoyant LDL cholesterol (lbLDL-C) and small dense LDL cholesterol (sdLDL-C) with Sampson equation. Hemolysis and hematologic parameters were also evaluated.Among 91 patients included between September 2018 and June 2021, thirty-seven patients had history of ACS and 6 patients developed ACS during following year. In unadjusted logistic regression, total bilirubin was associated with ACS occurrence (RR: 1.2 [1.05-1.51] p = 0.013). Concerning lipid profile, non-HDL-C (RR: 0.87 [0.0.67-0.99] p = 0.04) and sdLDL-C (RR: 0.78 [0.49-0.96] p = 0.03) were associated with ACS occurrence decrease. C-reactive protein was associated with ACS occurrence (RR: 1.27 [1.065-1.85] p = 0.011).Based on these findings, this study demonstrated that several biomarker easily available can be used at steady state to predict ACS in the following year. The validation of these results are required to ensure the reproducibility of the findings.
Identifiants
pubmed: 38755670
doi: 10.1186/s12944-024-02135-8
pii: 10.1186/s12944-024-02135-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
140Informations de copyright
© 2024. The Author(s).
Références
Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376:1561–73.
pubmed: 28423290
doi: 10.1056/NEJMra1510865
Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National acute chest syndrome Study Group. N Engl J Med. 2000;342:1855–65.
pubmed: 10861320
doi: 10.1056/NEJM200006223422502
Li X, Dao M, Lykotrafitis G, Karniadakis GE. Biomechanics and biorheology of red blood cells in sickle cell anemia. J Biomech. 2017;50:34–41.
pubmed: 27876368
doi: 10.1016/j.jbiomech.2016.11.022
DeBaun MR, Rodeghier M, Cohen R, Kirkham FJ, Rosen CL, Roberts I, et al. Factors predicting future ACS episodes in children with sickle cell anemia. Am J Hematol. 2014;89:E212–217.
pubmed: 25088663
pmcid: 4866602
doi: 10.1002/ajh.23819
Spring J, Munshi L. Hematology emergencies in adults with critical illness: malignant hematology. Chest. 2022;S0012–3692(22):00248–3.
Allareddy V, Roy A, Lee MK, Nalliah RP, Rampa S, Allareddy V, et al. Outcomes of acute chest syndrome in adult patients with sickle cell disease: predictors of mortality. PLoS ONE. 2014;9:e94387.
pubmed: 24740290
pmcid: 3989222
doi: 10.1371/journal.pone.0094387
Koehl JL, Koyfman A, Hayes BD, Long B. High risk and low prevalence diseases: acute chest syndrome in sickle cell disease. Am J Emerg Med. 2022;58:235–44.
pubmed: 35717760
doi: 10.1016/j.ajem.2022.06.018
Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997;89:1787–92.
pubmed: 9057664
doi: 10.1182/blood.V89.5.1787
Rees DC, Gibson JS. Biomarkers in sickle cell disease. Br J Haematol. 2012;156:433–45.
pubmed: 22122125
doi: 10.1111/j.1365-2141.2011.08961.x
Domingos IF, Pereira-Martins DA, Sobreira MJVC, Oliveira RTD, Alagbe AE, Lanaro C, et al. High levels of proinflammatory cytokines IL-6 and IL-8 are associated with a poor clinical outcome in sickle cell anemia. Ann Hematol. 2020;99:947–53.
pubmed: 32140892
doi: 10.1007/s00277-020-03978-8
Bartolucci P, Habibi A, Khellaf M, Roudot-Thoraval F, Melica G, Lascaux A-S, et al. Score Predicting Acute chest syndrome during Vaso-occlusive crises in adult sickle-cell disease patients. EBioMedicine. 2016;10:305–11.
pubmed: 27412264
pmcid: 5006640
doi: 10.1016/j.ebiom.2016.06.038
Kassasseya C, Sekou K, Besse-Hammer T, Nzouakou R, Arlet J-B, Magnang J, et al. Validation of a predictive score of acute chest syndrome (presev-2 study) in adults. Blood. 2020;136:23.
doi: 10.1182/blood-2020-143035
Styles L, Wager CG, Labotka RJ, Smith-Whitley K, Thompson AA, Lane PA, et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol. 2012;157:627–36.
pubmed: 22463614
pmcid: 3349768
doi: 10.1111/j.1365-2141.2012.09105.x
Stankovic Stojanovic K, Steichen O, Lefevre G, Bachmeyer C, Avellino V, Grateau G, et al. High lactate dehydrogenase levels at admission for painful vaso-occlusive crisis is associated with severe outcome in adult SCD patients. Clin Biochem. 2012;45:1578–82.
pubmed: 22892192
doi: 10.1016/j.clinbiochem.2012.07.114
Zorca S, Freeman L, Hildesheim M, Allen D, Remaley AT, Taylor JG, et al. Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. Br J Haematol. 2010;149:436–45.
pubmed: 20230401
pmcid: 3212812
doi: 10.1111/j.1365-2141.2010.08109.x
Kuypers FA. Membrane lipid alterations in hemoglobinopathies. Hematol Am Soc Hematol Educ Program. 2007;68–73.
Kubong LN, Nya Biapa PC, Chetcha B, Yanou-Njintang N, Moor Ama VJ, Pieme CA. Relationship between higher atherogenic index of plasma and oxidative stress of a group of patients living with Sickle Cell Anemia in Cameroon. Adv Hematol. 2020;2020:9864371.
pubmed: 32256600
pmcid: 7103039
doi: 10.1155/2020/9864371
Seixas MO, Rocha LC, Carvalho MB, Menezes JF, Lyra IM, Nascimento VML, et al. Levels of high-density lipoprotein cholesterol (HDL-C) among children with steady-state sickle cell disease. Lipids Health Dis. 2010;9:91.
pubmed: 20799970
pmcid: 2940866
doi: 10.1186/1476-511X-9-91
Aleluia MM, da Guarda CC, Santiago RP, Fonseca TCC, Neves FI, de Souza RQ, et al. Association of classical markers and establishment of the dyslipidemic sub-phenotype of sickle cell anemia. Lipids Health Dis. 2017;16:74.
pubmed: 28399852
pmcid: 5387254
doi: 10.1186/s12944-017-0454-1
Yalcinkaya A, Unal S, Oztas Y. Altered HDL particle in sickle cell disease: decreased cholesterol content is associated with hemolysis, whereas decreased apolipoprotein A1 is linked to inflammation. Lipids Health Dis. 2019;18:225.
pubmed: 31861992
pmcid: 6924024
doi: 10.1186/s12944-019-1174-5
Rahimi Z, Merat A, Haghshenass M, Madani H, Rezaei M, Nagel RL. Plasma lipids in iranians with sickle cell disease: hypocholesterolemia in sickle cell anemia and increase of HDL-cholesterol in sickle cell trait. Clin Chim Acta. 2006;365:217–20.
pubmed: 16185676
doi: 10.1016/j.cca.2005.08.022
Ephraim RKD, Adu P, Ake E, Agbodzakey H, Adoba P, Cudjoe O, et al. Normal Non-HDL cholesterol, Low Total Cholesterol, and HDL cholesterol levels in Sickle Cell Disease patients in the steady state: a case-control study of Tema Metropolis. J Lipids. 2016;2016:7650530.
pubmed: 28078142
pmcid: 5203913
doi: 10.1155/2016/7650530
Ozturk OH, Can Y, Yonden Z, Motor S, Oktay G, Kaya H, et al. Lipoprotein subfraction profile and HDL-associated enzymes in sickle cell disease patients. Lipids. 2013;48:1217–26.
pubmed: 24113910
doi: 10.1007/s11745-013-3849-4
da Guarda CC, Yahouédéhou SCMA, Santiago RP, Fernandes CF, de Neres L, de Oliveira JSDS. Investigation of lipid Profile and Clinical manifestations in SCA Children. Dis Markers. 2020;2020:8842362.
pubmed: 32884585
pmcid: 7455829
doi: 10.1155/2020/8842362
Qu H-Q, Glessner J, Qu J, Mentch F, Campbell I, Sleiman P, et al. Metabolomic profiling for dyslipidemia in pediatric patients with sickle cell disease, on behalf of the IHCC consortium. Metabolomics. 2022;18:101.
pubmed: 36459297
pmcid: 9718871
doi: 10.1007/s11306-022-01954-z
Allali S, Elie J, Mayrand L, de Montalembert M, Taylor M, Brice J, et al. Sputum IL-6 level as a potential predictor of acute chest syndrome during vaso-occlusive crisis in children with sickle cell disease: exploratory prospective prognostic accuracy study. Am J Hematol. 2023;98:E175–8.
pubmed: 37096490
doi: 10.1002/ajh.26939
Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease. Blood. 2000;96:3276–8.
pubmed: 11050014
doi: 10.1182/blood.V96.9.3276
Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A New equation for calculation of Low-Density Lipoprotein Cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5:540–8.
pubmed: 32101259
doi: 10.1001/jamacardio.2020.0013
Sampson M, Wolska A, Warnick R, Lucero D, Remaley AT. A new equation based on the Standard Lipid Panel for calculating small dense low-density lipoprotein-cholesterol and its use as a risk-enhancer test. Clin Chem. 2021;67:987–97.
pubmed: 33876239
pmcid: 8260186
doi: 10.1093/clinchem/hvab048
Novelli EM, Gladwin MT. Crises in Sickle Cell Disease. Chest. 2016;149:1082–93.
pubmed: 26836899
doi: 10.1016/j.chest.2015.12.016
Dang NC, Johnson C, Eslami-Farsani M, Haywood LJ. Bone marrow embolism in sickle cell disease: a review. Am J Hematol. 2005;79:61–7.
pubmed: 15849760
doi: 10.1002/ajh.20348
Chaturvedi S, Ghafuri DL, Glassberg J, Kassim AA, Rodeghier M, DeBaun MR. Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype. Am J Hematol. 2016;91:1185–90.
pubmed: 27543812
doi: 10.1002/ajh.24539
Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–20.
pubmed: 24782338
doi: 10.1002/art.38690
Pei G, Qin A, Dong L, Wang S, Liu X, Yang D, et al. Prognostic value of triglyceride to High-Density Lipoprotein Cholesterol Ratio (TG/HDL-C) in IgA nephropathy patients. Front Endocrinol (Lausanne). 2022;13:877794.
pubmed: 35795149
doi: 10.3389/fendo.2022.877794
Lalanne-Mistrih M-L, Connes P, Lamarre Y, Lemonne N, Hardy-Dessources M-D, Tarer V, et al. Lipid profiles in French West Indies sickle cell disease cohorts, and their general population. Lipids Health Dis. 2018;17:38.
pubmed: 29506549
pmcid: 5836466
doi: 10.1186/s12944-018-0689-5
Niesor EJ, Nader E, Perez A, Lamour F, Benghozi R, Remaley A, et al. Red blood cell membrane cholesterol may be a Key Regulator of Sickle Cell Disease Microvascular complications. Membr (Basel). 2022;12:1134.
Westerman MP. Hypocholesterolaemia and anaemia. Br J Haematol. 1975;31:87–94.
pubmed: 1212438
doi: 10.1111/j.1365-2141.1975.tb00835.x
Vendrame F, Olops L, Saad STO, Costa FF, Fertrin KY. Differences in heme and hemopexin content in lipoproteins from patients with sickle cell disease. J Clin Lipidol. 2018;12:1532–8.
pubmed: 30219641
doi: 10.1016/j.jacl.2018.08.002
Yalcinkaya A, Samadi A, Lay I, Unal S, Sabuncuoglu S, Oztas Y. Oxysterol concentrations are associated with cholesterol concentrations and anemia in pediatric patients with sickle cell disease. Scand J Clin Lab Invest. 2019;79:381–7.
pubmed: 31187639
doi: 10.1080/00365513.2019.1627578
Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84:643–9.
pubmed: 7517723
doi: 10.1182/blood.V84.2.643.643
Feugray G, Dumesnil C, Grall M, Benhamou Y, Girot H, Fettig J, et al. Lactate dehydrogenase and hemolysis index to predict vaso-occlusive crisis in sickle cell disease. Sci Rep. 2023;13:21198.
pubmed: 38040880
pmcid: 10692321
doi: 10.1038/s41598-023-48324-w
Feugray G, Kasonga F, Grall M, Benhamou Y, Bobée-Schneider V, Buchonnet G, et al. Assessment of Reticulocyte and Erythrocyte parameters from Automated Blood counts in Vaso-Occlusive Crisis on Sickle Cell Disease. Front Med (Lausanne). 2022;9:858911.
pubmed: 35492334
doi: 10.3389/fmed.2022.858911
Feugray G, Kasonga F, Grall M, Dumesnil C, Benhamou Y, Brunel V, et al. Investigation of thrombin generation assay to predict vaso-occlusive crisis in adulthood with sickle cell disease. Front Cardiovasc Med. 2022;9:883812.
pubmed: 36277754
pmcid: 9579298
doi: 10.3389/fcvm.2022.883812
Ataga KI, Hinderliter A, Brittain JE, Jones S, Xu H, Cai J, et al. Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease. Hematology. 2015;20:289–96.
pubmed: 24801127
doi: 10.1179/1607845414Y.0000000171
Tumblin A, Tailor A, Hoehn GT, Mack AK, Mendelsohn L, Freeman L, et al. Apolipoprotein A-I and serum amyloid a plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. Haematologica. 2010;95:1467–72.
pubmed: 20378559
pmcid: 2930946
doi: 10.3324/haematol.2009.018044
Teixeira RS, Arriaga MB, Terse-Ramos R, Ferreira TA, Machado VR, Rissatto-Lago MR, et al. Higher values of triglycerides:HDL-cholesterol ratio hallmark disease severity in children and adolescents with sickle cell anemia. Braz J Med Biol Res. 2019;52:e8833.
pubmed: 31618296
pmcid: 6799940
doi: 10.1590/1414-431x20198833
Olabode OP, Akinlade OM, Babatunde AS, Abdulazeez MI, Biliaminu SA, Oyabambi AO, et al. Triglyceride/HDL-cholesterol ratio and plasminogen activator inhibitor-1 independently predict high pulse pressure in sickle cell trait and disease. Arch Physiol Biochem. 2020;126:166–71.
pubmed: 30145922
doi: 10.1080/13813455.2018.1499118
Niazi MRK, Chukkalore D, Jahangir A, Sahra S, Macdougall K, Rehan M, et al. Management of acute chest syndrome in patients with sickle cell disease: a systematic review of randomized clinical trials. Expert Rev Hematol. 2022;15:547–58.
pubmed: 35666654
doi: 10.1080/17474086.2022.2085089
Paul RN, Castro OL, Aggarwal A, Oneal PA. Acute chest syndrome: sickle cell disease. Eur J Haematol. 2011;87:191–207.
pubmed: 21615795
doi: 10.1111/j.1600-0609.2011.01647.x